Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results

Core Insights - Hansa Biopharma is hosting a virtual event on November 12, 2025, featuring transplant surgeons to discuss the medical journey of highly sensitized kidney transplant patients and the clinical relevance of the Phase 3 ConfIdeS study results [1][2]. Company Overview - Hansa Biopharma AB is a biopharmaceutical company focused on developing innovative treatments for rare immunological conditions, with a proprietary IgG-cleaving enzyme technology platform [12]. - The company is listed on Nasdaq Stockholm under the ticker HNSA and is based in Lund, Sweden [12]. Event Details - The virtual event will include a presentation of the topline results from the US Phase 3 ConfIdeS trial by the Chief Medical Officer, Richard Philipson, followed by a discussion on the challenges faced by highly sensitized patients [2]. - Distinguished transplant surgeons, Dr. Robert Montgomery and Dr. Matthew Cooper, will provide insights into the clinical implications of the study results and the potential impact on current transplant practices in the US [2]. Target Patient Group - Highly sensitized patients, who have pre-formed donor-specific antibodies (DSAs), represent about 10-15% of the total transplant waiting list in the US and Europe, facing significant challenges in finding compatible donor organs [5]. - These patients experience longer waiting times for transplants, which correlates with increased mortality risk [5]. Product Information - Imlifidase, marketed as IDEFIRIX, is an antibody-cleaving enzyme that has received conditional marketing approval in Europe for desensitization treatment in highly sensitized adult kidney transplant patients [8][9]. - The product has shown promise in enabling kidney transplantation by inactivating donor-specific antibodies, thus creating a window for successful transplants [9][10].